Lung Cancer Research Foundation and Boehringer Ingelheim Launch $2.25 Million Initiative to Target HER2-Mutant Lung Cancer
核心洞察
The Lung Cancer Research Foundation and Boehringer Ingelheim announced a $2.25 million research collaboration to advance understanding and treatment of HER2 (搜索)-mutant lung cancer through two new funding mechanisms.
The initiative includes a $1.5 million Team Science Award and $750,000 in Early Career Investigator Awards, addressing the critical need for novel therapeutic approaches in HER2 (搜索)-driven lung cancers.
HER2 (搜索) mutations occur in up to 4% of non-small cell lung cancer cases, with current treatments not being curative and resistance invariably developing despite recent FDA approval of trastuzumab deruxtecan.
The Lung Cancer Research Foundation (LCRF) and Boehringer Ingelheim have announced a $2.25 million research collaboration aimed at advancing the understanding and treatment of lung cancers harboring HER2 (搜索) mutations. The partnership establishes two new funding mechanisms: a Team Science Award and an Early Career Investigator Award, both focused on addressing critical gaps in HER2-mutant lung cancer research.
Addressing a Critical Unmet Medical Need
Lung cancer remains the leading cause of cancer deaths worldwide, accounting for an estimated 130,180 deaths annually in the United States alone. While the past 10 to 15 years have seen accelerated clinical trials and FDA approvals of targeted therapies for non-small cell lung carcinoma (NSCLC), driven by advances in molecular profiling of tumors, significant challenges remain in treating specific oncogenic drivers.
HER2 (搜索) mutations have been identified as potential oncogenic drivers in lung cancer, occurring in up to 4% of NSCLC cases. Despite two decades of clinical trials investigating anti-HER2 therapies in lung cancer, results have been largely disappointing. The landscape changed somewhat on August 11, 2022, when the FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic NSCLC whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
However, available treatments are generally not curative, and resistance invariably develops. Additionally, immunotherapeutic strategies have not been successful in treating lung cancers with EGFR (搜索) or HER2 (搜索) mutations, highlighting the urgent need for novel therapeutic approaches.
Collaborative Research Framework
The partnership reflects both organizations' belief that team-based approaches to solving complex issues have the greatest likelihood of achieving near-term patient impact, while funding early career investigators maintains the research continuum necessary for scientific breakthroughs.
"We believe that supporting scientists to pursue their curiosity is key to driving meaningful progress and innovation—and that collaboration is essential to bringing groundbreaking treatments to patients," said Bjoern Rueter, U.S. Vice President, Clinical Development and Medical Affairs at Boehringer Ingelheim. "We are excited to join forces with Lung Cancer Research Foundation as we embark on a new era for cancer research and create the Team Science and Early Career Investigator awards."
Dr. Antoinette Wozniak, Chief Scientific Officer for LCRF, emphasized the patient-focused mission driving the collaboration: "Delivering impact to patients is what drives LCRF's research program. Research collaborations like this will accelerate the pace of scientific discovery moving forward. Our shared commitment to improving outcomes for people living with lung cancer continues to provide hope."
Funding Structure and Research Focus
The LCRF|Boehringer Ingelheim Team Science Award on Innovative Approaches Toward the Treatment of HER2 (搜索)-Driven Lung Cancer represents a $1.5 million, three-year award designed for research teams whose proposals include closely integrated projects. These projects must focus on either the science behind HER2 mutations as oncogenic drivers of malignancy or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations.
The LCRF|Boehringer Ingelheim Early Career Investigator's Award on Innovative Approaches Toward the Treatment of HER2 (搜索)-Driven Lung Cancer totals $750,000, distributed as up to three two-year awards of $250,000 each, all focused on HER2 mutations research.
Application Process and Timeline
The funding opportunity follows a rigorous two-step review process. Letters of Intent will be accepted until midnight on July 29, 2025. Selected projects will then be invited to submit full proposals, with all applications subject to review by LCRF's Scientific Advisory Board.
The collaboration builds on LCRF's substantial research investment history, having funded 429 research grants totaling nearly $48 million to date—the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. This new partnership with Boehringer Ingelheim represents a significant expansion of resources dedicated to understanding and treating HER2 (搜索)-driven lung cancers, addressing a critical area where current therapeutic options remain limited and resistance mechanisms are poorly understood.